Listen Top Shows Blog

$Daratumumab shows remarkable benefit in relapsed or refractory MM - Prof Meletios A Dimopoulos$

Daratumumab shows remarkable benefit in relapsed or refractory MM - Prof Meletios A Dimopoulos

Update: 2016-07-30

Share

Description

Prof Meletios Dimopoulos presents, at a press conference at EHA 2016, the results of POLLUX, an open-label, randomised phase III study that evaluated the combination of daratumumab and lenalidomide and dexamethasone (daratumumab group) compared with lenalidomide and dexamethasone (control group) in patients with relapsed/refractory multiple myeloma.

Comments

In Channel

Safety and efficacy of imatinib generics - Prof Tomasz Sacha

Safety and efficacy of imatinib generics - Prof Tomasz Sacha

2016-07-3007:30

SGN-CD33A combined with HMA therapy produces high remission rates among older patients with AML - Dr Amir Fathi

SGN-CD33A combined with HMA therapy produces high remission rates among older patients with AML - Dr Amir Fathi

2016-07-3004:27

Improved survival in adult ALL - Dr Nina Toft

Improved survival in adult ALL - Dr Nina Toft

2016-07-3005:18

Meta-analysis of overall survival in multiple myeloma treated with lenalidomide - Dr Philip McCarthy

Meta-analysis of overall survival in multiple myeloma treated with lenalidomide - Dr Philip McCarthy

2016-07-3006:33

CD19 CAR T-cells effective with with low dose chemotherapy. - Dr Stephanie Goff

CD19 CAR T-cells effective with with low dose chemotherapy. - Dr Stephanie Goff

2016-07-3003:00

Evaluation of ibrutinib in treatment of CLL with 17p deletion - Dr Jeffrey Jones

Evaluation of ibrutinib in treatment of CLL with 17p deletion - Dr Jeffrey Jones

2016-07-3003:48

Killer antibodies against AML - Dr Mette Hazenberg

Killer antibodies against AML - Dr Mette Hazenberg

2016-07-3006:01

$Daratumumab shows remarkable benefit in relapsed or refractory MM - Prof Meletios A Dimopoulos$

Daratumumab shows remarkable benefit in relapsed or refractory MM - Prof Meletios A Dimopoulos

2016-07-3005:21

Stopping tyrosine kinase inhibitors in CML - Dr Johan Richter

Stopping tyrosine kinase inhibitors in CML - Dr Johan Richter

2016-07-3005:04

Blinatumomab improves survival in ALL patients - Prof Max S Topp

Blinatumomab improves survival in ALL patients - Prof Max S Topp

2016-07-3004:20

Pre-leukaemic clones that survive chemo linked to higher risk of AML recurrence - Dr Klaus Metzeler

Pre-leukaemic clones that survive chemo linked to higher risk of AML recurrence - Dr Klaus Metzeler

2016-07-3003:57

Mutations associated with imatinib response in CML - Katerina Polakova

Mutations associated with imatinib response in CML - Katerina Polakova

2016-07-3005:18

Nivolumab restores effective anti-tumour response in Hodgkin lymphoma - Dr Anas Younes

Nivolumab restores effective anti-tumour response in Hodgkin lymphoma - Dr Anas Younes

2016-07-3003:28

SL401 in patients with rare neoplasm - Prof Naveen Pemmaraju

SL401 in patients with rare neoplasm - Prof Naveen Pemmaraju

2016-07-3008:21

Sequencing multiple myeloma reveals a complex landscape of genetic lesions - Dr Niccolo Bolli

Sequencing multiple myeloma reveals a complex landscape of genetic lesions - Dr Niccolo Bolli

2016-07-3005:16

Cured AML patients generate anti-tumour antibodies that kill AML blasts - Dr Mette Hazenberg

Cured AML patients generate anti-tumour antibodies that kill AML blasts - Dr Mette Hazenberg

2016-07-3005:08

PD-1 enhances elotuzumab efficacy - Dr Natalie Bezman

PD-1 enhances elotuzumab efficacy - Dr Natalie Bezman

2016-07-3003:31

Novel therapies for older patients with AML and MDS - Dr Naval Daver

Novel therapies for older patients with AML and MDS - Dr Naval Daver

2016-07-3005:17

Results from the EURO-SKI cessation trial of TKIs in CML - Dr Johan Richter

Results from the EURO-SKI cessation trial of TKIs in CML - Dr Johan Richter

2016-07-3004:44

The latest in CLL from EHA 2016

The latest in CLL from EHA 2016

2016-07-3021:58

00:00

00:00

x

$Daratumumab shows remarkable benefit in relapsed or refractory MM - Prof Meletios A Dimopoulos$

Daratumumab shows remarkable benefit in relapsed or refractory MM - Prof Meletios A Dimopoulos

ecancer.org